AB-005
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
Systematic (IUPAC) name: [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone
|
|
| CAS Number | 895155-25-6 |
| PubChem (CID) | 11537652 |
| ChemSpider | 9712433 |
| ChEMBL | CHEMBL571330 |
| Chemical and physical data | |
| Formula | C23H32N2O |
| Molar mass | 352.51 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.
Legal status[edit]
Psychoactive products in New Zealand containing this drug have been given interim approval under recent psychoactive substances legislation.[2]
See also[edit]
References[edit]
- ^ Frost, J. M.; et al. (2010). "Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
- ^ Ministry of Health – Manatū Hauora "Interim Product Approvals", Ministry of Health NZ, New Zealand, 2 January 2013. Retrieved on 2 January 2013.
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
